Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes.
about
Skeletal muscle as a therapeutic target for delaying type 1 diabetic complicationsThe interplay of autoimmunity and insulin resistance in type 1 diabetesInsulin sensitivity and complications in type 1 diabetes: New insightsEarly diabetic nephropathy in type 1 diabetes: new insightsInteraction between advanced glycation end products formation and vascular responses in femoral and coronary arteries from exercised diabetic ratsInsulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM).Biomarkers of adiponectin: plasma protein variation and genomic DNA polymorphisms.Chronic peripheral hyperinsulinemia in type 1 diabetic patients after successful combined pancreas-kidney transplantation does not affect ectopic lipid accumulation in skeletal muscle and liver.Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function.The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.Leptin deficiency causes insulin resistance induced by uncontrolled diabetes.Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance.Assessment of intramuscular lipid and metabolites of the lower leg using magnetic resonance spectroscopy in boys with Duchenne muscular dystrophy.Metabolomics approach for analyzing the effects of exercise in subjects with type 1 diabetes mellitus.Low serum adiponectin levels in children and adolescents with diabetic retinopathyDelayed skeletal muscle mitochondrial ADP recovery in youth with type 1 diabetes relates to muscle insulin resistance.Intramyocellular lipid and insulin resistance: differential relationships in European and African Americans.Longitudinal Analysis of Adiponectin through 20-Year Type 1 Diabetes Duration.Insulin resistance and associated factors in patients with Type 1 Diabetes.Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays.Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathyFeatures of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes.Association of insulin sensitivity to lipids across the lifespan in people with Type 1 diabetes.The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity.Physiological and pathophysiological regulation of regional adipose tissue in the development of insulin resistance and type 2 diabetes.Modulation of lupus phenotype by adiponectin deficiency in autoimmune mouse modelsThe importance of palmitoleic acid to adipocyte insulin resistance and whole-body insulin sensitivity in type 1 diabetesAdiponectin promotes functional recovery after podocyte ablation.Adiponectin and leptin: potential tools in the differential diagnosis of pediatric diabetes?Cohort profile: the German Diabetes Study (GDS).Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?Skeletal muscle fat infiltration: impact of age, inactivity, and exercise.Early diabetic nephropathy: a complication of reduced insulin sensitivity in type 1 diabetes.Adiponectin deficiency modulates adhesion molecules expression and cytokine production but does not affect disease severity in the transfer model of colitis.Addressing insulin resistance in Type 1 diabetes.Effects of type 1 diabetes mellitus on skeletal muscle: clinical observations and physiological mechanisms.Cardiovascular risk in double diabetes mellitus--when two worlds collide.The broad clinical phenotype of Type 1 diabetes at presentation.S-allylcysteine Improves Streptozotocin-Induced Alterations of Blood Glucose, Liver Cytochrome P450 2E1, Plasma Antioxidant System, and Adipocytes Hormones in Diabetic RatsInsulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes.
P2860
Q26775403-C19EB8ED-8DF7-45AC-A204-1852AAEAF6CEQ26823862-98293D8E-ADE6-4423-89B6-8665C9252610Q27000205-AA451E11-278F-4135-BB27-2F62A710BA18Q27021632-619C1C96-DF32-413A-AFDC-2D5CA164135CQ27322359-DD5E222D-4EE2-48C0-A68F-EE1FEC33EB77Q30434577-4DF521E3-5C20-4EAB-9A93-0288137A4687Q33552031-29C189CD-81C8-463A-BBDC-18DECCED2D87Q33556535-00A7BE3E-89AF-41ED-8CC4-ADB9F94E19ECQ33736145-3BD18E35-09A9-4E58-9279-F30207727F49Q33771752-49BFB51B-E6FD-48D3-B04B-43FCB95D9CE3Q33930217-AE4A5D0B-24B0-4FC5-8A3E-80C97E93141FQ33930299-ABECBBBF-95FE-46D5-A011-21F6EA96C02BQ34081572-5DA4D165-24F0-4B3C-9F07-60AB44473B09Q34336580-6AD2FBCC-E3B5-432D-8802-CF0AB15FEE89Q34666575-4B8A93F2-784C-4D20-88B6-65DD006E79B0Q35004291-CA48879F-D056-4C84-A74F-7EC26C2CB005Q35209779-6E5E7983-E711-43CD-BC6B-3813626DFEF7Q35531487-299E24DD-DFB2-423F-8EE0-7FE575AFB15CQ35559139-72D5A7F8-319A-4150-932E-7BA8FC4FCA89Q35579643-F3D71090-B7B0-41F6-817C-0D6760631718Q35673446-5E03E7CA-4A8A-45B3-8D62-ABE1F1F42584Q35921374-01AA7CE0-A301-4164-93DF-4081B3D72BA0Q36091431-A60656ED-A947-41F4-9D6C-A0C4FA3FEAC1Q36404490-B0D8C7EA-51F6-4EE9-B6D5-54A6DB3FBDC3Q36404495-6D4C1719-DE84-46F5-AA35-111E01364A97Q36419531-B1EF48B9-D643-4B7B-80CD-F1BA82281BDDQ36508961-C3562B1D-FD1D-4E1F-B6CA-6B3C8FB3B262Q36574746-10EB9C5F-1BB0-4E50-B30C-0D5D159105A0Q36666515-FFF54D5A-AAE9-40C8-97FD-4F6B3A37BA1FQ36774677-40A4ABA5-79C6-4FA2-A744-81A2FEFF2D89Q36898042-5F0EC9B1-EF87-4F88-BE6C-AFFE349DFBF8Q37134834-C84DC1C2-03C9-4609-9F2A-69A78098688AQ37278013-4CE55B96-4AF3-457C-89F5-2EC83A4B1307Q37368285-17B3D015-C421-4828-BE31-732280AE87C6Q37381806-4218AB8F-DBCA-4857-9E8E-A5850BDCC6DBQ37791182-56E15000-E554-4B00-A212-2B9147603D16Q38001360-03D7CD55-2315-446B-828C-F3F7098F71BBQ38052934-8582D4A2-D6F0-446A-982F-C6CB85080F9CQ38549688-B743F1B1-7298-444A-8BD7-8A697C556C6CQ38642435-0F14BFC4-4AB4-4386-A500-9CE435D7B879
P2860
Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Insulin resistance, intramyoce ...... patients with type 1 diabetes.
@en
Insulin resistance, intramyoce ...... patients with type 1 diabetes.
@nl
type
label
Insulin resistance, intramyoce ...... patients with type 1 diabetes.
@en
Insulin resistance, intramyoce ...... patients with type 1 diabetes.
@nl
prefLabel
Insulin resistance, intramyoce ...... patients with type 1 diabetes.
@en
Insulin resistance, intramyoce ...... patients with type 1 diabetes.
@nl
P2093
P2860
P921
P1476
Insulin resistance, intramyoce ...... patients with type 1 diabetes.
@en
P2093
Alberto Battezzati
Alessandro Del Maschio
Antonio Secchi
Francesco De Cobelli
Gianluca Perseghin
Guido Lattuada
Livio Luzi
Lucia Piceni Sereni
Massimo Danna
Paola Maffi
P2860
P304
P356
10.1152/AJPENDO.00279.2003
P577
2003-08-21T00:00:00Z